Results 211 to 220 of about 16,195 (312)

Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study. [PDF]

BMC Pulm Med, 2023
Kocks J, Bosnic-Anticevich S, van Cooten J, Correia de Sousa J, Cvetkovski B, Dekhuijzen R, Dijk L, Garcia Pardo M, Gardev A, Gawlik R, van der Ham I, Janse Y, Lavorini F, Maricoto T, Meijer J, Metz B, Price D, Roman Rodriguez M, Schuttel K, Stoker N, Tsiligianni I, Usmani O, Voorham J, Leving MT.   +23 more
europepmc   +1 more source

Lactose engineering for better performance in dry powder inhalers

, 2016
Yahya Rahimpour, Hamed Hamishehkar
openalex   +1 more source

Preparation and Evaluation of Enhanced Alveoli-delivery Dry Powder Inhaler Formulations

, 2020
Jun Yee Tse, Kazunori Kadota
openalex   +2 more sources

Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study [PDF]

, 2016
Christer Janson, Thomas Lööf, Gunilla Telg, Georgios Stratelis, Folke Nilsson   +4 more
openalex   +1 more source

Comparative Characterization of Tiotropium and Formoterol Drug Combination in Metered Dose Inhaler and Dry Powder Inhaler for the Treatment of Chronic Obstructive Pulmonary Diseases

, 2023
Priyanka Gondhale-Karpe, Sonali Manwatkar, Binoy Varghese Cheriyan, Makarand Puri   +3 more
openalex   +1 more source

An Audio-Based Method for Assessing Proper Usage of Dry Powder Inhalers [PDF]

, 2020
Athina-Chara Eleftheriadou, Anastasios Vafeiadis, Antonios Lalas, Konstantinos Votis, Dimitrios Tzovaras   +4 more
openalex   +1 more source

Evaluation of Small Airways Dysfunction With Dupilumab Using Airway Oscillometry in Uncontrolled Severe Asthma

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 264-266, March 2025.
Kirsten E. Stewart, Chris RuiWen Kuo, Rory Chan, Brian J. Lipworth   +3 more
wiley   +1 more source

Pharmacometric‐Based Evaluation of Salmeterol and Its Metabolite α‐Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Salmeterol is a commonly used β2‐agonist included on the List of Prohibited Substances and Methods published by the World Anti‐Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its major metabolite, α‐hydroxysalmeterol, in plasma and urine after inhalation.
Paul Thoueille, Anne Danion, Morten Hostrup, Michael Petrou, Koen Deventer, Thierry Buclin, François R. Girardin, Irene Mazzoni, Olivier Rabin, Monia Guidi   +9 more
wiley   +1 more source

Nanoparticle-Based Dry Powder Inhaler Containing Ciprofloxacin for Enhanced Targeted Antibacterial Therapy. [PDF]

Pharmaceutics
Party P, Klement ML, Gaudio BM, Sorrenti M, Ambrus R.   +4 more
europepmc   +1 more source

Particle-based coarse-grained approach for simulating dry powder inhaler. [PDF]

Int J Pharm, 2021
Liu X, Sulaiman M, Kolehmainen J, Ozel A, Sundaresan S.   +4 more
europepmc   +1 more source